Ovarian cancer with high-level focal

ERBB2 amplification Ovarian cancer Pertuzumab Precision oncology Trastuzumab

Journal

Gynecologic oncology reports
ISSN: 2352-5789
Titre abrégé: Gynecol Oncol Rep
Pays: Netherlands
ID NLM: 101652231

Informations de publication

Date de publication:
Aug 2021
Historique:
received: 12 02 2021
revised: 03 05 2021
accepted: 12 05 2021
entrez: 7 6 2021
pubmed: 8 6 2021
medline: 8 6 2021
Statut: epublish

Résumé

Epithelial ovarian cancer (EOC) is usually diagnosed at an advanced stage and significantly contributes to cancer mortality in women. Despite multimodal treatment associating chemotherapy and surgery, most patients ultimately progress and require palliative systemic therapy. In EOC, the efficacy of anti-HER2 agents is minimal even after selecting patients for HER2 expression.

Identifiants

pubmed: 34095423
doi: 10.1016/j.gore.2021.100787
pii: S2352-5789(21)00091-6
pmc: PMC8165411
doi:

Types de publication

Case Reports

Langues

eng

Pagination

100787

Informations de copyright

© 2021 The Author(s).

Déclaration de conflit d'intérêts

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Références

Nature. 2011 Jun 29;474(7353):609-15
pubmed: 21720365
Cancer Treat Rev. 2019 Feb;73:1-9
pubmed: 30543930
Lancet Oncol. 2018 Oct;19(10):1372-1384
pubmed: 30217672
Int J Gynecol Cancer. 2019 Sep;29(7):1141-1147
pubmed: 31420414
JAMA. 2019 Jan 22;321(3):288-300
pubmed: 30667505
J Clin Oncol. 2010 Mar 1;28(7):1215-23
pubmed: 19901115
Clin Med Insights Oncol. 2016 Mar 28;10(Suppl 1):21-30
pubmed: 27042153
Ann Oncol. 2018 Oct 1;29(Suppl 4):iv259
pubmed: 30285216
Int J Gynecol Cancer. 2012 Nov;22(9):1483-8
pubmed: 23027040
J Clin Oncol. 2006 Sep 10;24(26):4324-32
pubmed: 16896006
Nat Rev Clin Oncol. 2020 Jan;17(1):33-48
pubmed: 31548601
Ann Oncol. 2019 Nov 1;30(11):1821-1830
pubmed: 31504139
J Clin Oncol. 2003 Jan 15;21(2):283-90
pubmed: 12525520
Lancet Oncol. 2019 Apr;20(4):518-530
pubmed: 30857956

Auteurs

Laure Thouvenin (L)

Department of Oncology, University Hospitals of Geneva (HUG), Geneva, Switzerland.

Mélinda Charrier (M)

Department of Oncology, University Hospitals of Geneva (HUG), Geneva, Switzerland.

Sophie Clement (S)

Department of Genetic Medicine, Laboratory and Pathology, University Hospitals of Geneva (HUG), Geneva, Switzerland.

Yann Christinat (Y)

Department of Genetic Medicine, Laboratory and Pathology, University Hospitals of Geneva (HUG), Geneva, Switzerland.

Jean-Christophe Tille (JC)

Department of Genetic Medicine, Laboratory and Pathology, University Hospitals of Geneva (HUG), Geneva, Switzerland.

Mauro Frigeri (M)

Department of Oncology, University Hospitals of Geneva (HUG), Geneva, Switzerland.

Krisztian Homicsko (K)

Multidisciplinary Oncology Center, Lausanne University Hospital (CHUV), Lausanne, Switzerland.

Olivier Michielin (O)

Multidisciplinary Oncology Center, Lausanne University Hospital (CHUV), Lausanne, Switzerland.

Alexandre Bodmer (A)

Department of Oncology, University Hospitals of Geneva (HUG), Geneva, Switzerland.

Pierre O Chappuis (PO)

Department of Oncology, University Hospitals of Geneva (HUG), Geneva, Switzerland.
Department of Genetic Medicine, Laboratory and Pathology, University Hospitals of Geneva (HUG), Geneva, Switzerland.

Thomas A McKee (TA)

Department of Genetic Medicine, Laboratory and Pathology, University Hospitals of Geneva (HUG), Geneva, Switzerland.

Petros Tsantoulis (P)

Department of Oncology, University Hospitals of Geneva (HUG), Geneva, Switzerland.

Classifications MeSH